Artelo Biosciences Enters Material Definitive Agreement
Ticker: ARTL · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1621221
Sentiment: neutral
Topics: material-agreement, filing-update
Related Tickers: ARTL
TL;DR
ARTL signed a big deal on Oct 15, 2025 - check the exhibits!
AI Summary
Artelo Biosciences, Inc. entered into a material definitive agreement on October 15, 2025. The filing also includes financial statements and exhibits related to this agreement. The company, formerly known as Reactive Medical Inc. and Knight Knox Development Corp., is incorporated in Nevada and headquartered in Solana Beach, California.
Why It Matters
This filing indicates a significant new contract or partnership for Artelo Biosciences, which could impact its future financial performance and strategic direction.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the specifics of this agreement are not detailed in the provided summary, requiring further investigation.
Key Players & Entities
- Artelo Biosciences, Inc. (company) — Registrant
- October 15, 2025 (date) — Date of earliest event reported
- Reactive Medical Inc. (company) — Former company name
- Knight Knox Development Corp. (company) — Former company name
- Nevada (jurisdiction) — State of incorporation
- Solana Beach, CA (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Artelo Biosciences, Inc. on October 15, 2025?
The provided text states that Artelo Biosciences, Inc. entered into a material definitive agreement on October 15, 2025, and that financial statements and exhibits are included, but does not specify the nature of the agreement.
What were Artelo Biosciences, Inc.'s former company names?
Artelo Biosciences, Inc. was formerly known as Reactive Medical Inc. and Knight Knox Development Corp.
In which state is Artelo Biosciences, Inc. incorporated?
Artelo Biosciences, Inc. is incorporated in Nevada.
Where are Artelo Biosciences, Inc.'s principal executive offices located?
Artelo Biosciences, Inc.'s principal executive offices are located at 505 Lomas Santa Fe, Suite 160, Solana Beach, CA 92075.
What is the SEC file number for Artelo Biosciences, Inc.?
The SEC file number for Artelo Biosciences, Inc. is 001-38951.
Filing Stats: 687 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2025-10-17 16:30:34
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ARTL The Nasdaq Stock Mar
Filing Documents
- artl_8k.htm (8-K) — 26KB
- artl_ex101.htm (EX-10.1) — 80KB
- 0001640334-25-001856.txt ( ) — 242KB
- artl-20251015.xsd (EX-101.SCH) — 5KB
- artl-20251015_lab.xml (EX-101.LAB) — 15KB
- artl-20251015_cal.xml (EX-101.CAL) — 1KB
- artl-20251015_pre.xml (EX-101.PRE) — 9KB
- artl-20251015_def.xml (EX-101.DEF) — 2KB
- artl_8k_htm.xml (XML) — 4KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On October 15, 2025, Artelo Biosciences, Inc. (the "Company") entered into a cooperation letter agreement (the "Agreement") with Daniel S. Farb and certain of his affiliates (collectively, the "Farb Parties"). Pursuant to the Agreement, Mr. Farb agreed to irrevocably withdraw his nomination of candidates for election to the Company's board of directors (the "Board") at the 2025 annual meeting of stockholders. Additionally, the Farb Parties agreed to certain standstill restrictions and voting commitments during the Restricted Period (as defined in the Agreement), including, among other things, (i) an obligation to vote shares of the Company's common stock beneficially owned by the Farb Parties, and that the Farb Parties have the right to vote, subject to certain limited exceptions, in favor of the election of each person nominated by the Board for election as a director, against any proposals to remove any member of the Board, and in accordance with the recommendation of the Board on all other proposals or business, and (ii) a restriction on the ability of the Farb Parties to acquire beneficial ownership of more than 8.0% of the then-outstanding shares of the Company's common stock. The Company and the Farb Parties also made certain customary representations, agreed to certain mutual non-disparagement obligations that remain in effect during the Restricted Period, and agreed to a general mutual release of claims with respect to one another for any matter arising on or prior to the date of the Agreement. The foregoing summary of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed with this Current Report on Form 8-K as Exhibit 10.1 and is incorporated by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Cooperation Letter Agreement dated October 15, 2025, among the Company and the Farb Parties 104 Cover Page Interactive Data File, formatted in inline XBRL. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARTELO BIOSCIENCES, INC. Date: October 17, 2025 /s/ Gregory D. Gorgas Gregory D. Gorgas President & Chief Executive Officer 3